Vaxfectin to be assessed with DNA malaria vacc
San Diego, USA-based biopharmaceutical firm Vical has signed a cooperative R&D collaboration with the US Naval Medical Research Center, which is designed to examine the former's novel vaccine adjuvant Vaxfectin in combination with an experimental anti-malaria DNA vaccine. It is hoped that the agent will increase the immunological response to the vaccine.
The company, which holds patents covering Vaxfectin's use in combination with DNA vaccines, said that it has provided the agent to academic researchers for several years. Currently, Vaxfectin is being assessed in combination with a DNA-based influenza vaccine (Marketletter April 12), and is expected to enter human trials later in the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze